Aarti Drugs' Q4 earnings showed a 6% decrease in EBITDA, with margins dipping to 12.2%. This is a shift from last year's margin of 13.8%, indicating potential challenges in profitability for the company.

Despite a rise in revenue, Aarti Drugs experienced a 12.2% decrease in Q4 profits compared to last year, indicating a challenge in translating increased sales into higher earnings.

Aarti Drugs reported a 12% decrease in Q4 net profit compared to last year, but managed a 6% increase in revenue for FY26. EBITDA grew by 2.7%. Shares ended the day at ₹367 on NSE, marking a 1.3% rise.

Aarti Drugs announces a net profit of INR 61.48 crore for FY25-26, as approved by the board. The company has reappointed its auditors and made changes to the Risk Management Committee, introducing a new member.

Bayer's drugs Nubeqa and Keredia are experiencing significant growth, boosting the Contract Development and Manufacturing Organization (CDMO) sector. Notably, Navin Fluorine and Aarti Drugs play crucial roles as CDMO partners for Bayer, with their contributions through Acutaas.